Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor (everolimus [RAD001]) in combination with exemestane, after progression of therapy with nonsteroidal aromatase inhibitors.

Next Previous
Trial Profile

A Phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor (everolimus [RAD001]) in combination with exemestane, after progression of therapy with nonsteroidal aromatase inhibitors.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 12 May 2016 Status changed from recruiting to active, no longer recruiting.
  • 19 May 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top